Clearside Biomedical Inc represents a commitment to innovation, patient care, and scientific advancement. As a leading biopharmaceutical company, Clearside Biomedical is dedicated to developing and delivering transformative treatments for blinding diseases. With a focus on targeted therapies and specialized drug delivery, the company strives to improve patients' quality of life and offer hope where none existed before. Clearside Biomedical values a collaborative approach, working closely with healthcare professionals, researchers, and regulatory bodies to develop breakthrough solutions. By combining cutting-edge technology and extensive research, Clearside Biomedical aims to revolutionize the treatment landscape for ocular diseases.

Clearside Biomedical Inc is primarily present in the United States.

Clearside Biomedical Inc has achieved several significant milestones. One notable accomplishment is the successful completion of the HULK study, evaluating the efficacy and safety of CLS-TA for patients with macular edema associated with non-infectious uveitis. Additionally, the company received approval for their proprietary suprachoroidal CLS-TA drug-delivery platform by the U.S. Food and Drug Administration (FDA). Clearside Biomedical Inc also completed a public offering to raise funds for advancing their research and development efforts. Through their continuous innovations and regulatory achievements, Clearside Biomedical Inc demonstrates their commitment to improving treatment options for ophthalmic diseases.

Clearside Biomedical Inc is a reputable pharmaceutical company involved in the development of innovative ophthalmic treatments. Founded in 2011, Clearside Biomedical focuses on providing therapies for sight-threatening ocular diseases. The company primarily specializes in the use of proprietary SCS Microinjector® technology, which enables the precise delivery of drugs to the targeted site within the eye. With a strong commitment to advancing patient care, Clearside Biomedical conducts extensive research and clinical trials to develop effective solutions for diseases like macular edema and uveitis. With an impressive track record and a dedication to innovation, Clearside Biomedical Inc continues to make significant contributions to the field of ophthalmology.

The main competitors of Clearside Biomedical Inc in the market are other biotechnology companies focusing on developing innovative ophthalmic therapies.

Clearside Biomedical Inc is primarily active in the pharmaceutical and biotechnology industries.

Clearside Biomedical Inc's business model focuses on developing and commercializing innovative therapies to treat blinding diseases of the eye. The company utilizes its proprietary SCS Microinjector® to deliver targeted treatments to the affected areas of the eye, providing a non-surgical and convenient approach for patients. Clearside Biomedical Inc primarily focuses on developing treatments for conditions like macular edema, uveitis, and diabetic macular edema. By leveraging their expertise in ocular drug delivery, the company aims to improve patient outcomes and address unmet medical needs in the field of ophthalmology.

Το Clearside Biomedical P/E είναι -2,01.

Το KUV της εταιρείας Clearside Biomedical είναι 134,46.

Το AlleAktien Qualitätsscore για το Clearside Biomedical είναι 4/10.

Ο κύκλος εργασιών του αναμενόμενη Clearside Biomedical είναι 565.375,80 USD.

Το αναμενόμενη Clearside Biomedical κέρδος είναι -37,80 Εκ. USD.

Clearside Biomedical Inc is a biopharmaceutical company that specializes in developing innovative therapies for the treatment of eye diseases. The company's business model is based on the development and marketing of safe and effective drugs that improve patients' vision and quality of life.

Η Clearside Biomedical καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Clearside Biomedical αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Clearside Biomedical είναι US1850631045.

Το WKN της Clearside Biomedical είναι A2ALP6.

Ο τίκερ της Clearside Biomedical είναι CLSD.

Κατά τους τελευταίους 12 μήνες η Clearside Biomedical κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Clearside Biomedical προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Clearside Biomedical ανέρχεται σήμερα στο .

Clearside Biomedical πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Clearside Biomedical πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Clearside Biomedical ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Clearside Biomedical από την 16/9/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 16/9/2024.

Η τελευταία μερίσματος έγινε στις 16/9/2024.

Το έτος 2023, η Clearside Biomedical διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Clearside Biomedical καταβάλλονται σε USD.